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Re-Orientation of Clinical Research in Traumatic
Brain Injury: Report of an International Workshop
on Comparative Effectiveness Research
Andrew I.R. Maas,1 David K. Menon,2 Hester F. Lingsma,3 Jose A. Pineda,4
M. Elizabeth Sandel,5 and Geoffrey T. Manley 6

Abstract

During the National Neurotrauma Symposium 2010, the DG Research of the European Commission and the
National Institutes of Health/National Institute of Neurological Disorders and Stroke (NIH/NINDS) organized
a workshop on comparative effectiveness research (CER) in traumatic brain injury (TBI). This workshop reviewed existing approaches to improve outcomes of TBI patients. It had two main outcomes: First, it initiated a
process of re-orientation of clinical research in TBI. Second, it provided ideas for a potential collaboration
between the European Commission and the NIH/NINDS to stimulate research in TBI. Advances in provision of
care for TBI patients have resulted from observational studies, guideline development, and meta-analyses of
individual patient data. In contrast, randomized controlled trials have not led to any identifiable major advances.
Rigorous protocols and tightly selected populations constrain generalizability. The workshop addressed additional research approaches, summarized the greatest unmet needs, and highlighted priorities for future research.
The collection of high-quality clinical databases, associated with systems biology and CER, offers substantial
opportunities. Systems biology aims to identify multiple factors contributing to a disease and addresses complex
interactions. Effectiveness research aims to measure benefits and risks of systems of care and interventions in
ordinary settings and broader populations. These approaches have great potential for TBI research. Although
not new, they still need to be introduced to and accepted by TBI researchers as instruments for clinical research.
As with therapeutic targets in individual patient management, so it is with research tools: one size does not fit all.
Key words: comparative effectiveness research; clinical research; clinical trials; methodology; systems biology;

traumatic brain injury
vehicles in low- and middle-income countries (Maas et al.,
2008). Vulnerable road users (pedestrians, cyclists, and motorcyclists) are at high risk. The World Health Organization
(WHO) predicts that deaths from road traffic incidents (primarily due to TBI) will double between 2000 and 2020, and
that this increase will come exclusively in low- and middleincome countries (WHO/OMS, 2009).
In developed, westernized societies the occurrence of TBI is
mainly increasing in people aged over 60 years (https://
webgate.ec.europa.eu/idb/documents/2009-IDB-Report_
screen.pdf; http://www.cdc.gov/traumaticbraininjury/tbi_
ed.html). In the past, a TBI in this age group was thought to

Introduction
Epidemiologic considerations

T

he worldwide importance of traumatic brain injury
(TBI) requires an effective, widely applicable response.
The annual incidence of TBI is estimated at up to 500/100,000
in the U.S. and Europe, and results in over 200 per 100,000
individuals being admitted to hospitals each year in Europe
(Langlois et al., 2006; Maas et al., 2008; Styrke et al., 2007;
Tagliaferri et al., 2006). Epidemiological surveillance suggests
that the nature of TBI is changing over time. Globally the
incidence is increasing, due mainly to greater use of motor
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lead to a uniformly bad outcome; however, current experience
is that a favorable outcome is possible and not uncommon.
Nevertheless, the classic age range for inclusion in many
clinical trials excludes such people and makes trial data less
relevant to their treatment (Dhruva and Redberg, 2008). Another development is that the increasing burden of TBI due to
military conflicts, and the exposure of civilians in combat
zones has modified the epidemiology and clinical pattern of
TBI (Risdall and Menon, 2011). Worldwide, TBI has devastating effects on patients and their relatives and results in
high socioeconomic costs to society. This necessitates a
widespread international effort to combat TBI and improve
outcomes.
Discordance between experimental and clinical
success: The complexity of clinical research in TBI
Research in basic science has disclosed that multiple
mechanisms are involved in the pathophysiology of TBI
(Marklund et al., 2006). This has led to the development of
many neuroprotective agents with promising potential, but
none have yielded benefits in clinical testing. The gap between
bench and bedside raises the question of why benefits from
seemingly effective interventions have not been seen in large
randomized clinical trials. One explanation for this discrepancy may be that the clinical situation is far more complex and
unpredictable than that seen with experimental models of
TBI. Experimentally, the type and degree of injury can be
standardized, while in the clinical situation wide variability
exists, both in type (e.g., diffuse and focal injuries) and in
severity of injury. In the clinical situation, pretreatment is
impossible, and intervention within short therapeutic windows can be challenging. Adverse effects of systemic insults,
such as hypoxia and hypotension, on outcome might easily
overwhelm any benefit from a new therapy. The identification
of relevant covariates and the development of robust prognostic models by the CRASH (MRC CRASH Trial Collaborators, 2008) and IMPACT (Steyerberg et al., 2008)
collaborations are very useful for dealing with the heterogeneity of the TBI population. However, adjustments for baseline prognostic risk ignore the contribution of aspects of care,
such as the quality of intensive care and rehabilitation, on
outcome. For example, data from the NABISH-I study (Clifton et al., 2001) showed that inter-center variations in clinical
care could produce substantial noise in results of clinical trials.
Recent findings from the IMPACT studies have shown that
the risk of poor outcomes could differ between centers, and is
up to three times higher than would be expected by chance
after adjustment for baseline prognostic risk (Lingsma et al.,
2011). How much of the observed variability reflects variability in clinical management is unknown.
The impact that variability of care may have on clinical
outcomes requires rigorous examination, because identification of underlying causes could result in real improvements in
outcomes. Identification of best clinical practices and efforts to
minimize recognized variances in care (Clifton et al., 2001),
through, for example, ‘‘Six Sigma’’ processes (Schweikhart
and Dembe, 2009), may yield benefits. These may exceed
those provided by research addressing a single aspect in the
continuum of care. It is therefore important to undertake more
implementation-based research to ensure that current and
future effective therapies are translated into improving clini-
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cal outcomes in everyday clinical practice. To quote Goethe,
‘‘Knowing is not enough; we must apply. Willing is not enough; we must do.’’
These considerations provided the context for the DG
Research of the European Commission and NIH/NINDS
to organize a workshop during the National Neurotrauma
Symposium 2010 on comparative effectiveness research
(CER).
The aims of this workshop on CER were to: (1) perform a
critical re-appraisal of approaches to clinical research in TBI;
(2) identify the greatest unmet needs from a clinical perspective; (3) discuss the potential of CER in the field of TBI; and (4)
explore the possibility and the added value of a joint EU-U.S.
effort in this field. This article summarizes the results of this
workshop.
Approaches to clinical research in TBI: What has
(and has not) made a difference?
Clinical trials. Traditionally, the efficacy of new treatments has been investigated in randomized controlled trials
(RCTs). In TBI, these trials have been conducted on a range of
neuroprotective agents and surgical and medical approaches
(Maas et al., 2010a). Whereas various single-center studies
have reported benefits of a range of interventions (for example
hyperbaric oxygen, mannitol, hypothermia, and decompressive craniectomy), none of these findings were generalizable in multicenter RCTs. Furthermore, substantial selection
bias may have existed in reporting benefits in single-center
studies (Maas et al., 2010a). For example, of the 20 multicenter
studies on neuroprotective agents, only one reported a significant treatment benefit: the HIT III study researchers
(Harders et al., 1996) found a beneficial effect of the calcium
channel modulator nimodipine, but targeted only patients
with traumatic subarachnoid hemorrhage. The generalizability of this relatively small study (n = 123) is therefore
questionable, and taken in combination with negative results
from three other studies on nimodipine, these findings have
not changed clinical practice.
At the other extreme, a mega-trial of steroids in TBI was
halted early because of increased mortality at 14 days in patients treated with corticosteroids (Roberts et al., 2004), but
did not show a significant effect on quality of outcome at
6 months (Edwards et al., 2005).
It is not surprising that the past decade has seen a sharp
decline in the number of clinical trials initiated in TBI, particularly in those on neuroprotective agents (Fig. 1). This may
be due to disappointment in the results of previous studies,
along with the perception that TBI is a high-risk and costly
indication. Increasing overhead costs required by academic
research institutions in the EU and U.S. contribute significantly to the high cost of clinical trials, in some cases
amounting to or even exceeding 100% overhead, which
doubles the amount of funding required to conduct the trial.
The result is that academic institutions are pricing themselves
out of the market, and a clear shift in research has been seen
towards the Far East and Latin America, where the potential
for patient recruitment is higher and study costs are lower
(Maas et al., 2010a).
However, there is uncertainty whether findings obtained
in these settings may be extrapolated to higher-income
countries, and about the importance of components of care
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FIG. 1. Number of clinical trials initiated over the past 30 years, differentiated by studies of neuroprotective agents versus
therapeutic strategies. Adapted from Maas et al., 2010a.

systems. As the search for effective therapies continues, there
is a need for comparative studies in which differences, for
example in access to acute and post-acute care, in trauma
organization, and in treatment, may be explored and the
consequences for generalizability estimated.

cols that are sometimes difficult to replicate in the wider
clinical care spectrum. The discrepancy between clinical trial
data and real world practice, and the need for other approaches to gathering evidence as a basis for clinical management, was highlighted 15 years ago (Black, 1996).

Guideline development. Some consistency in approach to
care has been achieved by management guidelines
(www.tbiguidelines.org; www.nice.org.uk; Maas et al., 1997).
Most of these guidelines are evidence-based, and follow a
rigorous and systematic analysis of the available literature.
Despite isolated reports that suggest otherwise (Cremer et al.,
2005), most reports show that adoption of such guidelines has
resulted in improvements in TBI mortality and functional
outcome (Bulger et al., 2002; Clayton et al., 2004; Elf et al.,
2002; Fakhry et al., 2004; Patel et al., 2002; Stein et al., 2010;
Suarez et al., 2004; Varelas et al., 2006). Nevertheless, the level
of evidence underpinning the guidelines is, on average, only
low. Of the 229 recommendations contained in seven guideline publications, only four are based on class I evidence
(Table 1).
The limited number of recommendations that are supported by high-quality evidence is not unique to TBI, but has
also been noted in other fields of medicine. A recent review of
practice guidelines developed by the American College of
Cardiology and the American Heart Association found that
relatively few recommendations were based on high-quality
evidence from overviews of RCTs, and many were based
solely on expert opinion, individual case studies, or standard
of care (Tricoci et al., 2009).
The paucity of high-quality evidence reflects the many
uncertainties about the benefits and risks of multiple treatment approaches, and the limited funding available for TBI
clinical research. We will never be able to mount adequately
powered trials to address all of these uncertainties. Furthermore, traditional clinical trials do not address the effect of
different clinical practices available in the real world, and
have limited external validity since the effect of treatment is
evaluated in selected populations, with management proto-

Observational studies. Although relatively small in
comparison to the number of clinical trials conducted in TBI,
observational studies have had a substantial impact upon
clinical management.
The Glasgow group initiated prospective data collection on
severe head injury in 1968, and expanded this to an international level in 1972, including centers from the U.S. and the
Netherlands ( Jennett et al., 1976, 1977, 1980). These studies
were facilitated by the introduction of the Glasgow Coma
Scale (GCS) and the Glasgow Outcome Scale (GOS), both of
which are still universally accepted for classification of initial
injury severity and outcome. Treatment approaches were
compared, and extensive prognostic studies revealed that
age, GCS score, and pupillary reactivity were the main predictors of outcome in severe TBI, and prognostic rules were
developed.
The Traumatic Coma Data Bank (TCDB; 1984–1987) prospectively collected data from four U.S. centers (Foulkes et al.,
1991). This study highlighted the importance of systemic
hypoxia and hypotension as determinants of outcome
(Chesnut et al., 1993).
More recent reports suggest that physiological insults
continue to be an issue, both in the emergency room and in the
critical care unit context (Hlatky et al., 2004; Manley et al.,
2001). Numerous studies in animal models have confirmed
the significance of these clinical observations, while adding to
our understanding of the pathological mechanisms involved
(DeWitt et al., 1995; Ishige et al., 1988; Statler et al., 2001). A
major advance employed in the TCDB was the Marshall CT
classification as a descriptive measure for the type of brain
damage and the risk of increased intracranial pressure (ICP).
Further studies have confirmed its importance as a prognostic
parameter (Maas et al., 2007b).
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Table 1. Evidence-Based Guidelines for Management of Traumatic Brain Injury (TBI):
Strength of Recommendations
Recommendations (n)
Guideline
Prehospital management
Penetrating brain injury
Pediatric guidelines
U.K. guidelines for triage,
assessment, investigation,
and management of TBI
Field management of
combat-related head trauma
Surgical management of TBI
Revised guidelines for management
of severe TBI
Total

Reference

Topics (n)

Class I

Class II

Class III

Brain Trauma Foundation, 2000
Aarabi et al., 2001
Adelson et al., 2003
U.K. National Institute for Health
and Clinical Excellence, 2003

7
7
17
27

0
0
0
3

5
0
6
16

12
12
40
107

Brain Trauma Foundation, 2005

5

0

3

15

Bullock et al., 2006
Brain Trauma Foundation, 2007

5
15

0
1

0
14

26
17

83

4

44

229

Classification of evidence on therapeutic effectiveness

a

Class I lack sufficient patient numbers, or suffer from other methodological inadequacies that render them
class II or III.
Class II that were based on reliable data. Comparison of two or more groups must be clearly distinguished. Types
of studies include observational, cohort, prevalence, and case-control. Class II evidence may also be derived
from flawed RCTs.
Class III Types of studies include case series, databases or registries, case reports, and expert opinions. Class III
evidence may also be derived from flawed RCTs, cohort, or case-control studies.
a
From Guidelines for the Management of Severe Traumatic Brain Injury, 3rd ed., Brain Trauma Foundation, www.tbiguidelines.org.
In the NICE guidelines (http://www.nice.org/), the grading scheme for level of recommendations was adapted from the Oxford Centre for
Evidence Based Medicine levels of evidence as level A–D; for consistency, we considered grade A class I, grade B as class II, and grades C and
D as class III.

The core data survey conducted by the European Brain
Injury Consortium (EBIC) concerned a 3-month data collection period in moderate and severe TBI across 67 centers
(Murray et al., 1999). This study resulted in four publications
and demonstrated the evolution of CT lesions over time
(Servadei et al., 2000), as well as the importance of traumatic
subarachnoid hemorrhage (Servadei et al., 2002). Wide variations in intensive care management were reported across
participating centers, without evidence of an association with
improved outcomes (Stocchetti et al., 2001).
In an analysis of patients with head injury from the registry
of the Trauma Audit and Research Network (TARN) in the
U.K., Patel and associates (2005) found that improvements
over time in outcomes of patients with head injuries were less
than those observed in other trauma patients. Patients with
severe head injuries treated in a hospital without a neurosurgeon had a 2.15-fold increase in the odds of death after
adjustment for case mix, compared to those treated in a unit
with neurosurgical facilities.
Meta-analysis of individual patient data. The IMPACT
studies (Maas et al., 2007a) brought together individual patient data from eight RCTs and three observational studies
(n = 9205; Marmarou et al., 2007). Relevant parameters from
the individual studies were merged into a large dataset,
forming a ‘‘culture medium’’ for exploring concepts for improving the design of clinical trials in TBI (Maas et al., 2007a).
The IMPACT studies have yielded important contributions to
advance the field of clinical research in TBI. Extensive prognostic analysis has defined and quantified more precisely the

predictive value of many known predictors, has yielded new
predictors, and has resulted in the presentation of validated
prognostic models for use in moderate and severe TBI
(Steyerberg et al., 2008). These models have much wider applications than only in the context of trial design (Lingsma
et al., 2010). Simulation studies demonstrated that broad inclusion criteria, pre-specified covariate adjustment, and an
ordinal analysis all promote an efficient trial, yielding gains in
statistical efficiency of over 40%. This means that smaller but
clinically relevant treatment effects can now be detected
without increasing trial size or duration, and these findings
have the potential to revolutionize the design and analysis of
clinical trials in TBI (Maas et al., 2010b).
In summary, major advances in understanding and improving TBI care have come not from clinical trials, but from
observational studies, guideline development, and metaanalysis of individual patient data. Rigorously conducted
observational studies in large and diverse populations have
the potential to identify better clinical practices and to reshape
care for patients with TBI in the future.
A critical re-appraisal of the experience within and across
clinical trials in TBI illustrates the inadequacies of approaches
to study design and analysis, clinical assessments, classification, and management.
Bridging the gap between bench and beside
The possible causes for translational failures in clinical
neuroprotection in TBI have been addressed in many previous publications (Green, 2002; Ikonomidou and Turski, 2002;
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Maas et al., 1999; Narayan et al., 2002; Tolias and Bullock,
2004). One of the aspects highlighted during the panel discussions of the workshop was the uncertain relevance of results obtained from experimental studies in rodents to human
subjects, reflecting differences in brain development, brain
anatomy, and physiology. While studies in lissencephalic
species may continue to be useful in elucidating and antagonizing disease mechanisms, a strong plea was heard to implement more intermediate studies in larger gyrencephalic
mammals, such as pigs and sheep, before clinical translation is
attempted. An alternative or adjunctive approach to such
large animal studies may be more preparatory clinical research, including the use of strategies to optimize candidate
therapies before initiation of formal Phase II trials in patients
( Janowitz and Menon, 2010). In TBI, perhaps uniquely among
acute CNS diseases, conventional protocols for clinical care
provide unparalleled access to key biological compartments
through techniques such as microdialysis, ventriculostomy,
and jugular bulb catheterization. This access, and the common
use of serial imaging (universally with computed tomography
[CT], but increasingly with magnetic resonance imaging
[MRI], and sometimes with positron emission tomography
[PET]), provides opportunities to examine disease mechanisms, drug pharmacokinetics, and proof of principle of
therapy in small, well-designed studies. We suggest that those
monitoring and investigation tools that are commonly used in
patients with TBI may provide a route to facilitate a more
rational approach to translational research. This suggestion is
underpinned by existing research data on disease biology,
drug delivery, and treatment response obtained with these
methods ( Janowitz and Menon, 2010).

MAAS ET AL.
Classification
General approaches to classification of TBI are by cause
(mechanistic) and severity. In clinical practice the conventional categorization of the severity of brain injury is primarily
based on the GCS score. While the GCS represented a significant advance in the characterization of TBI, more recent
studies suggest that its accuracy and prognostic power in
more severely injured patients may be reduced due to effects
of early sedation, neuromuscular blockade, and ventilation
(Czosnyka et al., 2005; Stocchetti et al., 2004). Further, it
should be realized that the commonly employed differentiation into mild (GCS score 13–15), moderate (GCS score 9–12),
and severe (GCS score 8 or less) injury is artificial, and that
clinical severity lies on a continuum. Pathoanatomical and
pathophysiological processes may occur across the spectrum
of clinical severity, but may vary in frequency and severity.
Moreover, patients with similar clinical severity as assessed
by the GCS may have widely differing types of injury (Fig. 2).
Additional major issues are the physiological vulnerability of
patients with TBI, particularly of those with moderate or severe injury and extracranial injuries. Thus the classification of
TBI is multidimensional and complex. A recent authoritative
workshop has made a strong case for a new and more comprehensive categorization of TBI in clinical trials (Saatman
et al., 2008). The workshop also recommended the development of a common data set of TBI data elements, and the
establishment of a large prospective patient database across
the spectrum of injury severity. Common data elements have
been proposed (Maas et al., 2011), but a large prospective data
set is still required.
Mechanistic targeting

Genetic make-up and response to injury
A major gap in knowledge concerns different responses to
similar injuries. Such patient-specific differences could in part
be genetically determined, and much research will be needed
in the areas of genomics and metabolomics to elucidate the
wide variability in the response to brain injury. The relevance
of genetics may be seen by the observation that recovery is
poorer in patients with stroke or TBI who have the APOE e4
allele than in those who do not have this allele (Alexander
et al., 2007). Other genes for which evidence exists for associations with outcomes are the TP53, COMT, DRD2, CACNA1A, and BCL2 genotypes ( Jordan, 2007; Zangrilli Hoh
et al., 2010).
Premorbid factors and comorbidity
The importance of premorbid factors and comorbidity
has often been neglected in TBI, on the assumption that primarily young and otherwise healthy subjects are afflicted.
Awareness of the increase of TBI in older people and in
those with prior problems has changed this. A recent analysis
revealed that one in four U.S. citizens now lives with at least
two chronic comorbidities (Parekh and Barton, 2010). These
comorbidities imply impaired physiological reserve and a
range of pre-existing medications (including anticoagulant
therapy and platelet aggregation inhibitors). These factors
will influence both disease course (e.g., via more hemorrhagic
expansion), and the pharmacokinetic interactions and pharmacodynamic safety of new therapies in TBI.

Different pathophysiological processes may occur simultaneously or sequentially, and to varying degrees. The concept of mechanistic targeting—the ideal for clinical trials—
will require reliable identification of occurrence and time
course of pathophysiological mechanisms in individual
patients. There is the emerging hope that multimodality
monitoring may allow us to differentiate between pathophysiologies that appear superficially similar, but require
different treatment. For example, the combination of conventional monitoring with brain tissue oximetry and microdialysis may allow us to differentiate between classical
ischemia (which may respond to cerebral perfusion pressure
[CPP] elevation), and diffusion hypoxia (Menon et al., 2004),
or mitochondrial dysfunction (Vespa et al., 2005), which may
respond to normobaric hyperoxia (Nortje et al., 2008). The
emerging fields of advanced MRI imaging and of proteomic
biomarkers offer opportunities for detection and tracking of
pathophysiological processes.
Individualizing clinical management
Protocol-driven approaches are currently the standard in
the treatment of TBI. These approaches are often poorly
focused, utilizing a stepwise approach, with an escalating
intensity of therapy, regardless of the underlying pathophysiology. They adhere to the concept of a ‘‘one pill for everybody’’ approach. The introduction of novel monitoring
technology, and advances in neuroimaging techniques, now
offer opportunities for advancing care from a one-size-fits-all

TBI AND COMPARATIVE EFFECTIVENESS RESEARCH

37

FIG. 2. Types of brain injury may differ greatly in patients with similar initial clinical severity as assessed by the Glasgow
Coma Scale. Adapted from Saatman et al., 2008 (EDH, extradural hematoma; DAI, diffuse axonal injury; SDH, subdural
hematoma; SAH, subarachnoid hemorrhage; IVH, intraventricular hemorrhage).
approach, to a more focused approach, targeted to the needs
of an individual patient. The concept of individualized management is closely related to the possibilities for mechanistic
targeting. There are clear benefits to be gained from the employment of personalized approaches. For example, the curve
of the relationship between CPP and outcome shows an inverted ‘‘U’’ shape, suggesting that there is an optimum level of
CPP, and that higher or lower levels are disadvantageous
(Balestreri et al., 2006). Indeed, the use of management
schemes that incorporate vigorous CPP augmentation can
result in significant cardiorespiratory complications (Robertson et al., 1999). Further, there is accumulating evidence
that the optimum level of CPP varies between patients, and
the optimum level in a given patient may be identifiable using
autoregulatory indices (Howells et al., 2005; Steiner et al.,
2002), or brain oximetry (Spiotta et al., 2010).
Early end-points and mechanistic targets
Major advances in the fields of cardiovascular medicine,
oncology, and AIDS research have resulted from the use of
early (mechanistic) end-points, for example troponin in
myocardial infarction and CD4 counts in HIV. In TBI, however, early end-points that reliably predict quality of recovery
are not yet available. In the past, ICP has been used, either
explicitly or implicitly, as a surrogate end-point, especially in
early-stage trials in clinical TBI. While this approach has some
merit, it is important to recognize two important confounders.
First, modern neuro-ICU practices have substantially
blunted our ability to use ICP as a surrogate marker in this
way. It is possible to control ICP by intensifying ICP/CPP
therapies until the system terminally decompensates and intracranial hypertension becomes refractory to therapy. In this
context, the intensity of ICP/CPP-targeted therapy may be

more relevant than the actual values of ICP. Second, the use of
ICP as a surrogate outcome marker neglects the side effects of
therapies (Coles et al., 2002, 2007). The importance of complications following, for example decompressive craniectomy, was recently demonstrated in the DECRA trial
(Cooper et al. 2011).
A more rational option would be to use definitive markers
of tissue fate in the brain. Biomarkers may have great potential in TBI (Table 2). Advances in this emerging field offer
hope for the identification of biochemical and other markers
that are clinically relevant for quantifying and tracking disease processes. Further, if we could use patients as their own
controls in determining if an intervention altered the trajectory of neuronal loss, we could at least determine whether a
neuroprotective intervention was initially effective, in that it
reduced incremental tissue injury. Serial MRI with diffusion
tensor imaging (DTI; Niogi et al., 2008), and MR spectroscopy
(Ashwal et al., 2006; Govind et al., 2010), may provide clinically viable methods of assessing such incremental neuronal
losses, but this approach needs to be tested in large

Table 2. Potential Uses for Biomarkers
in Traumatic Brain Injury (TBI)
 Establishing a diagnosis of TBI (relevant to mild cases)
 Assessing the severity and nature of TBI
 Monitoring the evolution of injury and recovery in individual patients or groups of patients
 Defining treatments needed
 Monitoring of treatment effects
 Mechanistic target for clinical trials
 Prediction of outcome
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prospective studies that map the temporal trajectories of lesion evolution with conventional treatment.
Post-acute assessments and care
Consistent standardized methods are largely lacking to
track service utilization and changes in functional status following acute care discharge. Where they do exist, general use
is often inhibited by the copyright protection imposed by
developers. In comparison to acute care studies, post-acute
studies are often small in size and research is fragmented. In
particular, there is little continuity in research between acute
and post-acute care studies. Nevertheless, disparities in access
to post-acute care may influence the recovery process and
confound interpretation of outcomes. A major challenge in the
post-acute care phase is posed by the highly variable time
periods at which data are recorded, confounding comparability of studies and interpretation of their results. Thus a
great need exists for more prospective longitudinal studies
bridging the gap between acute and post-acute research in
TBI.

MAAS ET AL.
consistent with post-traumatic stress disorder (PTSD) are reported in up to 40% of military personnel returning from
deployment following mild blast TBI (Hoge et al., 2008), although the study is controversial because it may have underestimated the percentage of patients with mild TBI who
experienced PTSD (Correspondence NEJM, 2009). Questions
persist concerning the best methods for the determination of
the neurological and/or psychological aspects and etiologies
of these interrelated disorders (Bryant, 2008). In one study
using survey techniques for military personnel injured in Iraq
and Afghanistan, researchers found that 12% of respondents
reported a history consistent with mild TBI, and 11% screened
positive for PTSD (Schneiderman et al., 2008). Advanced
neuroimaging techniques such as MRI spectroscopy offer
opportunities for the diagnosis of brain abnormalities in this
population (Hoge et al., 2009). Civilian TBI studies have rarely
included measures of PTSD, and consequently the incidence
of this combined diagnosis is unknown in civilian populations. There is clearly a great need for further research in this
area, including studies that allow us to differentiate more
accurately between PTSD and the sequelae of TBI in all
populations.

Outcome
The GOS is currently accepted by investigators and regulatory authorities alike as the standard end-point for judging
efficacy in a cohort of patients with TBI. Outcome after TBI,
however, is by definition multidimensional, including neurophysical disabilities, disturbances in mental functioning
(e.g., cognitive and executive functioning), and consequent
problems in social reintegration. Moreover, even the Extended GOS is relatively insensitive in its upper ranges, and
may therefore be less suited for patients with milder injuries.
Recently, the Neurological Outcome Scale for TBI (NOS-TBI)
has been proposed as an effective and simple tool to quantify
neurological deficits after TBI (Wilde et al., 2010). This approach already takes some multidimensional aspects of outcome assessment into consideration.
Relatively few TBI studies have utilized Health-Related
Quality of Life (HRQoL) measures. There is a need for comprehensive disease-specific instruments for HRQoL assessment in persons after TBI, such as the novel disease-specific
scale Quality of Life in Brain Injury (QOLIBRI; Truelle et al.,
2010; von Steinbuechel et al., 2005, 2010a, 2010b). There is a
need to develop a multidimensional approach to outcome
assessment and classification, including the patient’s quality
of life.
Psychological health and TBI
The workshop on ‘‘An Integrated Approach to Research in
Psychological Health and TBI,’’ organized by NIH/NINDS,
the Department of Defense, the Department of Veteran Affairs, and the National Institute on Disability and Rehabilitation Research in October 2008, revealed the previously
unrecognized relationship between these two seemingly unrelated disciplines (Thurmond et al., 2010). First, substance
abuse is common in victims of TBI and may often be a contributing factor in injury mechanism. Second, depression and
anxiety disorders are relatively frequent in survivors, and this
may adversely affect social reintegration and confound outcome assessments. Mental health and chronic pain are considered key areas, both pre- and post-injury. Third, symptoms

Pediatric considerations
Despite past and current prevention efforts, TBI continues
to kill and disable more children and adolescents than any
other cause (Forsyth et al., 2008; Langlois et al., 2005). There is
a paucity of widely-applied, effective therapies, and results
from adult studies may not be applicable to children. While
conducting research in pediatric TBI, researchers need to
carefully balance the need for better therapies and delivery of
care with the consideration that children with TBI are a vulnerable population in whom to conduct research. There is
only fragmented understanding of disease biology, and the
frequency and geographical distribution of pediatric TBI
create unique challenges for researchers (Natale et al., 2006).
Translation of knowledge and effective therapies from the
bench to the bedside are of particular significance in pediatric
TBI. While a body of research has provided important preclinical data, TBI models in immature animals have unique
limitations, including differences in brain development between humans and the species used in the laboratory, injury
mechanics, and evaluation of recovery (Prins and Hovda,
2003). Pre-clinical studies have and will continue to make
contributions to the field, but more work needs to be done to
improve our understanding of the biology of TBI in children.
It is through this understanding that the suitability of a given
mechanism as a target for therapy can best be defined. Ongoing efforts to understand the pathobiology of pediatric TBI
will build on previous single-center studies with limited
sample sizes, and the consequent need to use pooled samples
(Kochanek et al., 2000). Such an approach has value, but
results in fragmented descriptions of the time course of
the pathological cascades under study, and limits external
validity.
Variability in aspects of clinical care can affect the applicability of controlled studies to the general population. For
example, children with severe TBI can be admitted to adult
hospitals, adult trauma centers (with or without pediatric
qualifications), pediatric hospitals, or pediatric trauma centers. Furthermore, it is estimated that 17,000,000 children in
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the United States do not have timely access to high-level pediatric trauma care (Carr and Nance, 2010). Transport decisions are influenced by geographic factors and emergency
medical service practices. Variability of clinical care within
and between pediatric centers adds to these challenges. Many
of the challenges described in the adult TBI population are
magnified when it comes to pediatric TBI. Specific considerations concern injury classification, the transition from acute
to sub-acute care, and the selection of optimal outcome
measures that include measurements of quality of life and
evaluations of psychological health (Winthrop, 2010). As researchers address these challenges, the dynamic nature of
human development needs to be taken into account when
evaluating injury type, physiological values (such as CPP and
cerebral blood flow [CBF]), and cell injury mechanisms and
recovery (e.g., language, executive function, and measures of
independence; Kapapa et al., 2010; Kochanek, 2006; Walker
et al., 2009).
During the workshop, a review of the international networks available to conduct research in pediatric TBI revealed
numerous opportunities and highlighted challenges. Identification and understanding of best clinical practices through
CER may help optimize and homogenize care delivery, facilitating mechanistic targeting and the implementation of
future effective therapies. Whether via RCTs, rigorously
conducted observational studies, or other forms of CER, understanding pediatric TBI requires strong collaboration
among multiple centers and across countries and continents.
Alternative Approaches and Priorities for Clinical
Research in Traumatic Brain Injury
The issues summarized above highlight the complexity of
the challenges facing clinical TBI research. Priorities for clinical research are summarized in Table 3. A strong collaborative international effort will be required to address these.
In the absence of possibilities for mechanistic targeting, the
traditional approach to clinical trials in TBI has been to decrease heterogeneity in patient populations by employing
restrictive enrollment criteria. The disadvantage of this approach is that it is statistically inefficient and decreases external validity. The question is if attempts to limit
heterogeneity are appropriate, or alternatively, that the existing heterogeneity in patient populations, management approaches, and outcomes, may be used to advantage by
exploring these differences and analyzing the underlying
causes for a given outcome or individual patient response to a
selected therapy or intervention. Classical clinical trials, with
large numbers and substantial costs, may not be suitable vehicles for providing answers to all of the questions that we
have. We need alternative approaches to address these
questions. One direction to in which to proceed is the prospective collection of large, multi-scalar (demographics,
physiology, proteomics, genomics, and outcome), longitudinal, high-quality clinical databases, associated with systems
biology and CER methods.
A Systems Biology Approach
Traditional clinical trials and studies have relied upon a
hypothesis-driven, model-based approach. While this reductionistic approach has been very successful in developing
treatments for infectious diseases and cancer, where single
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Table 3. Summary of Unmet Needs and Priorities
for Clinical Research
 Bridge the gap between bench and bedside
- Promote interaction between basic scientists and clinical
researchers in order to better scale experimental models
to reflect human pathology both physically and pathologically
- Experimental work-up should include testing in larger
animals
- Better optimization of candidate drug molecules in clinical
disease through experimental medicine approaches
- Develop mechanistic end-points in human traumatic
brain injury (TBI), such as biomarkers and advanced
neuro-imaging
 Integrate acute and post-acute care research
 Develop a novel approach to the classification of TBI, also
considering extracranial injuries
 Develop a multidimensional approach to outcome assessment, including the patient perspective (quality of life)
 Explore the influence of gender and genetic makeup on
disease course and outcome
 Develop tools to better capture clinical variability
 Use information on clinical variability to develop and test
strategies for individualized management
 Prediction research
- Outcome: update/validate prognostic models
- Prediction of treatment response
- Prediction of the expected trend using monitored
parameters
- Prediction of the risk of hemorrhagic expansion
 Involve information technology personnel and other experts
from unrelated fields in explorations of novel approaches to
classification (pattern recognition), and prediction research
(machine learning techniques)
 ‘‘Open source’’ research: data sharing and data standardization
 A particular focus on pediatric and elderly subpopulations
 Collaborate with psychological health and pain experts
 Ensure that improvements in therapy are applicable to
settings where they are needed most (developing economies)
 Explore whether findings obtained in a particular setting
(e.g., developing economies) may be extrapolated to other
settings

organisms or cell types are responsible for the pathology,
there has been only limited success using this approach for
more heterogeneous complex diseases, such as inflammatory
disease, diabetes, and cardiovascular disease. In these complex disorders there is likely no single factor that is responsible for the disease. This is particularly true for disorders of
the central nervous system, such as traumatic brain injury, for
which there is significant heterogeneity in the etiology, pathology, mechanisms, and outcome.
In contrast to the reductionistic, hypothesis-driven approach that seeks to target a single variable responsible for the
disease, a systems biology approach aims to identify multiple
factors that contribute to the disease. Systems biology also
addresses the complex interactions of these multiple variables
in a multivariate, multidimensional manner, over time. Systems biology is a rapidly growing interdisciplinary field that
combines biology, mathematics, statistics, and computer science, to better understand complex biological processes.
In this regard systems biology may be better considered an
‘‘informational science’’ approach, in which hypotheses are
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data driven and seek to describe the behavior of the entire
system. In lay terms, it is the description of the forest instead
of the trees. There are now numerous examples of the application of the systems approach to complex biological problems, particularly in microorganisms (Bischofs et al., 2009;
Spiro et al., 1997), and more recently complex human disease
(Chen et al., 2009; Sears et al., 2009). These studies demonstrate how a systematic, integrative analysis that includes
genes, proteins, and behavior over time, can solve complex
problems that are insufficiently addressed by the conventional, reductionistic approach.
Comparative effectiveness research
RCTs—generally considered to be the gold standard—
address efficacy rather than effectiveness. Efficacy reflects the
degree to which an intervention produces the expected result
under carefully controlled conditions chosen to maximize the
likelihood of observing an effect if it exists. The study population and setting of efficacy studies may differ in important
ways from those settings in which the interventions are likely
to be used. By contrast, CER intends to measure differences in
outcome and to relate these to the package of care and its
constituent components in ordinary settings and broader
populations. It can therefore be more relevant to policy evaluation and the health care decisions of providers and patients
(Table 4; IOM, 2009).
Many different official definitions of CER exist. Common
characteristics are presented in Table 5.
The call for CER does not mean that all research must have
these characteristics. Early studies of an intervention should
also compare it to a placebo, standard care, or no intervention.
During early development of a new intervention, it is critical
to determine safety and efficacy under a defined set of circumstances (IOM, 2009).
Examples of comparative effectiveness research
in TBI
The concept of CER in TBI is not new. In 1983 Gelpke and
associates analyzed differences in outcome between two
centers from the Netherlands (Rotterdam and Groningen)
participating in the International Data Bank of severe head
injury. The 1-year survival rate in Rotterdam was 45% versus
63% in Groningen. The research question was whether the
difference in survival rate was due to differences in the initial
severity of the injury or to a difference in management efficacy. Of the 18% difference in survival rate, 10.5% was due to
differences in severity of injury on admission. The remaining
7.5% difference in survival rate was not explained, but may
have been caused by unmeasured variations in the initial
determination of severity of injury or by differences in management. Groningen had a more conservative management
approach than Rotterdam. For example, artificial ventilation

Table 4. The Different Intents of Randomized
Controlled Trials (RCTs) and Comparative
Effectiveness Studies (CERs)
Efficacy
Effectiveness

Can it work?
Does it work?

Adapted from Drummond et al., 2008.

RCT
CER

Table 5. Common Characteristics of Comparative
Effectiveness Research
 The objective of directly informing a specific clinical
decision from the patient perspective, or a health policy
decision from the population perspective
 Comparison of at least two alternative interventions, each
with the potential to be a best practice
 Description of results at the population and subgroup
levels
 The use of outcomes—both benefits and harms—that are
important to patients
 Employment of methods and data sources appropriate for
the decision of interest
 Interventions conducted in settings that are similar to
those in which the intervention will be used in practice

was used in 43% of the Rotterdam cases and in 14% of the
Groningen cases. The authors concluded that the results of
their study did not support the concept that an aggressive
management regimen would improve outcome. However,
the efficacy with which aggressive management was implemented and the impact on target pathophysiological variables (such as cerebral perfusion pressure and carbon dioxide
control) was not analyzed.
This study can be considered a CER study, although performed long before this type of research was recognized as a
separate and important entity or even had a name. It used
observational data from a setting that represents clinical
practice. It measured a patient-relevant outcome, and the
study aimed to inform medical decision making.
Similarly, the comparative analysis of treatment results
between Charlottesville (U.S.) and New Delhi (India) reported
by Colohan and colleagues in 1989 qualifies as CER. An almost 8% higher mortality was found in patients with a localizing motor response in New Delhi (12.5% versus 4.8%).
The relative absence of pre-hospital emergency care and the
delay in admission after head injury were considered as two
possible causes for these differences (Colohan et al., 1989).
A more recent example of CER comes from the IMPACT
studies. Here, differences in outcome between centers were
quantified across 10 RCTs and three observational studies,
containing data on 9578 patients with moderate and severe
TBI (Lingsma et al., 2011). The between-center differences in
unfavorable outcome (dead, vegetative state, or severe disability as measured with the Glasgow Outcome Scale) at 6
months were estimated with a random effects logistic regression model. An odds ratio (OR) was estimated for each
center by comparing the number of patients with unfavorable
outcome to the average, set at an OR of 1. The authors found
that the 95% range of ORs among centers was 0.55–1.83,
meaning that there are centers in which the odds of unfavorable outcome are almost half the average, and centers
where the odds of unfavorable outcome approach twice the
average. There is thus a more than threefold difference in the
probability over and above chance effects to have an unfavorable outcome between the centers, which could not be
explained by adjustment for the most important predictors of
outcome in TBI: age, GCS motor score, and pupil reactivity.
Limitations resulting from the nature of the IMPACT database (inconsistent recording of relevant variables across
multiple studies) unfortunately precluded a detailed
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comparative analysis aimed at exploring possible underlying
causes in depth. The observed center differences clearly
demonstrate the potential for CER in TBI and the importance
of rigorously conducted, comprehensive, consistent, prospective data collection across multiple centers. One key step
in such efforts will be the development of common data elements for TBI (CDEs), and the implementation of web-based,
efficient data collection tools (Maas, 2009; Maas et al., 2010c,
2011).
A further example of the application of CER to TBI—and
now in the setting of post-acute care—is based upon standardized data collection performed by the Kaiser Permanente
health system in the U.S. Kaiser Permanente (KP) serves the
health care needs of 8.2 million members in nine states and the
District of Columbia, including California, Colorado, Georgia,
Hawaii, Maryland, Ohio, Oregon, Virginia, and Washington.
The KP system offers a unique opportunity to compare variation of care and outcomes. Much of the data concerning an
encounter or episode of care is standardized, and permits
comparison of populations based on demographic characteristics, care settings and trajectories, service delivery, and
also outcomes by mining and analyzing data. In the KP
Northern California Region (KP-NCAL), where membership
currently stands at 3.2 million members, the annual incidence
of acute brain injury is approximately 2500, and a large-scale
genetics database is being created that will be available for TBI
studies. In 2002, The Division of Research in Oakland (KPNCAL) created a large mild TBI registry that is also available
for research studies. KP has internally funded a study of TBI to
determine the risk of development of Alzheimer’s disease that
was to be completed at the end of 2010.
With the availability of large databases and variability in
utilization of services, an opportunity exists to study the
variation in outcomes of care delivery. For KP-NCAL neurotrauma patients, care may be initially provided outside the
system, in a non-KP trauma center or an emergency room. For
example, KP-NCAL patients may receive acute trauma care at
San Francisco General Hospital, a Level 1 trauma center, or
Kaiser South Sacramento, a Level 2 trauma center, or in a KP
emergency department. Patients with mild TBI are often seen
in emergency departments, within or outside the KP integrated health care system, and released to home with a referral to their primary care physicians. Others are referred
to specialists, for example at the regional rehabilitation
center or elsewhere, by local trauma centers. Physiatric comanagement with a primary care provider, or evaluation by a
neuropsychologist, may also be an important model to study.
Studies of inpatient hospital versus skilled nursing facility
versus home or outpatient care may be further developed
using this approach.
The future potential of comparative
effectiveness research in TBI
There are many unanswered questions in TBI, that relate to
the process of care, trauma organization, and specific approaches. Many uncertainties concerning best clinical practice
exist in TBI.
How should acute trauma care and post-acute care be organized? Does time to referral to a specialist for post-acute
care matter? Can any preference in the post-acute care setting
be found for inpatient hospital versus skilled nursing facility
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versus home or outpatient care? Management issues in the
acute care of more severely injured patients include which
treatment modalities for treating ICP should be used and in
what sequence. Uncertainty exists about the optimal timing
for extracranial surgery, and for the indications and timing of
surgery for contusions and for treatment of raised ICP.
There are four unique features of TBI that make CER a
feasible approach to address these uncertainties.
First, there are large between-center differences and between-country differences in both outcome and management.
On one hand these differences might be considered worrisome. On the other hand they provide a major opportunity to
compare alternative interventions/management strategies/
care organization that all are possible best practices, in everyday clinical practice.
Second, robust covariates and validated prognostic models
have been developed specifically for TBI by the CRASH and
IMPACT collaborations (MRC CRASH Trial Collaborators,
2008; Steyerberg et al., 2008). These models provide the possibility to adjust for patient characteristics that affect outcome.
Third, advanced statistical models, including random effects models, are available to analyze differences between
centers.
Fourth, recommendations have been developed for standardization of data collection and coding of variables.
However, what is currently still lacking in TBI is the existence of a contemporary observational dataset with highquality, uniformly-collected highly granular, prospective
data. This is crucial to performing high-quality CER studies. It
has been argued that data for CER research might be drawn
from ongoing clinical trials. This approach would, however,
violate a main principle of CER studies, namely that they
should be conducted in settings similar to those in which the
intervention will be used in practice. Moreover, the experience
from the IMPACT studies illustrates that in-depth CER analysis of such data is not possible if specific research interests,
such as treatment-specific effects, have not been predetermined and data collection targeted accordingly. We argue that contemporary prospective data collection is essential
and should be carried out through a coordinated effort involving a large number of clinical centers in several countries.
This initiative would require a significant investment in terms
of time and money. However, such an investment would be
certainly repaid by the results that would stem from the CER
analysis of the collected data. CER research has the potential
to answer the many open questions in TBI, and further offers
opportunities for cost utility studies in the context of health
technology assessment in TBI.
Conclusions
In many ways this workshop points to a paradigm shift in
clinical research in TBI. First, the joint organization by European and U.S. funding agencies reflects the need for international collaboration. Second, we have come to realize that
approaches other than the reductionistic methods of strictly
controlled trials should be considered in clinical TBI research.
Improved clinical care of TBI patients will likely depend on
a range of research approaches, including systems biology
and CER. These approaches are not yet widely used in clinical
TBI research, first because of unfamiliarity, second because of
the lack of a rich and comprehensive human dataset that
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includes demographic, clinical, genomic, proteomic, imaging,
and detailed outcome data across multiple time points. It is
essential that CER studies comply with published guidelines
for such studies (Sox et al., 2010). The lower costs of this type
of approach make it particularly attractive for studies that
otherwise would be cost-prohibitive. Well conducted studies
will translate into clinically meaningful results, which will
directly inform decision making in clinical practice, and thus
improve care for TBI patients. An important barrier to systems biology approaches is cultural, in which this new datadriven systems approach challenges the current reductionistic
approach to clinical research, and requires a new way of
thinking about human biology and disease. It also requires
multidisciplinary teams of investigators from disciplines that
have not previously worked together to apply and refine
these promising mathematical and computational tools.
Overcoming existing prejudice will require vision and sufficient and sustained funding.
However relevant these approaches may be, it is important
that we do not view them as the new panacea in TBI research.
As with therapeutic targets in individual patient management, so it is with research tools in populations of patients:
one size does not fit all.
The joint organization of the workshop by European and
U.S. funding agencies holds promise. It reflects the agencies’
interest in joining efforts to move the TBI field forward, and
this was confirmed during the American Association for the
Advancement of Science meeting (Washington, D.C., February 2011), when the EU commission and the NIH jointly organized a session on ‘‘transatlantic synergies to promote
effective traumatic brain injury research.’’ An international
collaborative initiative would be timely and of significant
added value for the TBI field. Constituting an observational
dataset with data of quality high enough to perform system
biology approaches and CER studies requires a sizable economic effort. Given the observational nature of these approaches, there is a limited probability that it would be
funded by industry. Governmental agencies are thus the most
plausible source of funding. Furthermore, the necessity of
enrolling a large number of clinical centers across different
countries would rule out the possibility of the funding coming
from a single country. The need for an international collaborative research effort is evident. We argue that this would
offer a much-needed opportunity to provide answers to the
many open questions in TBI research, and improve care for
TBI patients.
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